Cathie Wood Biogen Inc. Transaction History

Ark Investment Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 01, 2019	SELL	$278.5 - $352.75 $6.27 Million - $7.94 Million	-22,498 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$293.51 - $383.83 $2.48 Million - $3.24 Million	8,448 Added 60.13%	22,498 $7.95 Million
Q2 2018 Aug 07, 2018	SELL	$257.52 - $306.91 $7,725 - $9,207	-30 Reduced 0.21%	14,050 $4.08 Million
Q1 2018 May 14, 2018	BUY	$260.13 - $367.91 $1.95 Million - $2.76 Million	7,501 Added 114.01%	14,080 $3.86 Million
Q4 2017 Feb 12, 2018	BUY	$307.64 - $344.58 $710,956 - $796,324	2,311 Added 54.15%	6,579 $2.1 Million
Q3 2017 Nov 09, 2017	BUY	$281.15 - $329.69 $373,367 - $437,828	1,328 Added 45.17%	4,268 $1.34 Million
Q2 2017 Aug 11, 2017	SELL	N/A	-368 Reduced 11.12%	2,940 $798,000
Q1 2017 May 15, 2017	SELL	N/A	-35 Reduced 1.05%	3,308 $904,000
Q4 2016 Feb 13, 2017	BUY	N/A	3,343	3,343 $948,000

1,036

126M

1.13M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $22.7B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Ark Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Ark Investment Management LLC and Cathie Wood with notifications on news.